Guanilib: Phase IIa started

Synergy Pharmaceuticals Inc. (OTCBB:SGYP, New York, N.Y.) began a double-blind, placebo-controlled, dose-escalation Phase IIa trial to evaluate 1, 3 and 9 mg oral SP-304 daily for 14 days in patients...